Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare joint tumor: drug shrinks growths without surgery

NCT ID NCT04488822

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times

Summary

This study tests a drug called pexidartinib in 40 adults with a rare joint tumor (TGCT) that causes severe symptoms and cannot be helped by surgery. The main goal is to see if the drug shrinks the tumors after 25 weeks of treatment. Participants take the drug daily and are monitored for safety and tumor response using MRI scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beijing Ji Shui Tan Hospital

    Beijing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Peking University Cancer Hospital

    Beijing, China

  • Shanghai General Hospital

    Shanghai, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.